Literature DB >> 2204659

Ursodeoxycholic acid treatment for chronic cholestatic liver disease.

O F James1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204659     DOI: 10.1016/0168-8278(90)90263-q

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  7 in total

Review 1.  Primary biliary cirrhosis.

Authors:  J Neuberger; M Lombard; R Galbraith
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Protective effect of tauroursodeoxycholate against acute gastric mucosal injury induced by hydrophobic bile salts.

Authors:  M Muraca; E Zanusso; V Cianci; M T Vilei; P Pazzi; M Dalla Libera; S Gamberini
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 3.  Therapeutic uses of animal biles in traditional Chinese medicine: an ethnopharmacological, biophysical chemical and medicinal review.

Authors:  David Q-H Wang; Martin C Carey
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 4.  Pathophysiology and clinical basis of prevention and treatment of complications of chronic liver disease.

Authors:  S Wagner; H U Lautz; M J Müller; F W Schmidt
Journal:  Klin Wochenschr       Date:  1991-02-06

5.  Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans.

Authors:  H U Marschall; H Matern; H Wietholtz; B Egestad; S Matern; J Sjövall
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

6.  A controlled trial of high dose interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B: long term follow up.

Authors:  V Perez; J Findor; H Tanno; J Sordá
Journal:  Gut       Date:  1993       Impact factor: 23.059

Review 7.  Substitutes for Bear Bile for the Treatment of Liver Diseases: Research Progress and Future Perspective.

Authors:  Sha Li; Hor Yue Tan; Ning Wang; Ming Hong; Lei Li; Fan Cheung; Yibin Feng
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-21       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.